Clinical and Research Diagnostic Criteria for Alzheimer's Disease

Neuroimaging Clinics of North America

Volumn 22, Issue 1, 2012, Pages 23-32

  Sarazin, Marie ^a,b,c,d,e   de Souza, Leonardo Cruz ^a,b,c,d,e   Lehéricy, Stéphane ^a,b,c,d,e   Dubois, Bruno ^a,b,c,d,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer; Biomarkers; MCI; Memory testing; New criteria

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CARBON 11; FLUORODEOXYGLUCOSE; PITTSBURGH COMPOUND B; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; BRAIN ATROPHY; BRAIN DAMAGE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; HIPPOCAMPUS; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LANGUAGE DISABILITY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; CLINICAL MEDICINE; HUMANS; NEUROIMAGING; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 84856293013     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2011.11.004     Document Type: Review

References (59)

1. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
2. Ballard C., Gauthier S., Corbett A., et al. Alzheimer's disease. Lancet 2011, 377(9770):1019-1031.
3. Blacker D., Albert M.S., Bassett S.S., et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative. Arch Neurol 1994, 51:1198-1204.
4. Dubois B., Feldman H.H., Jacova C., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
5. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
6. Bouwman F.H., Verwey N.A., Klein M., et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010, 30:1-7.
7. de Jager C.A., Honey T.E., Birks J., et al. Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis. Int J Geriatr Psychiatry 2010, 25(10):988-997.
8. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008, 29:669-675.
9. Albert M.S., Dekosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
10. DeKosky S.T., Carrillo M.C., Phelps C., et al. Revision of the criteria for Alzheimer's disease: a symposium. Alzheimers Dement 2011, 7:e1-e12.
11. Jack C.R., Albert M.S., Knopman D.S., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
12. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
13. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
14. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
15. Dubois B., Albert M.L. Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurol 2004, 3:246-248.
16. Buschke H., Sliwinski M.J., Kuslansky G., et al. Diagnosis of early dementia by the double memory test: encoding specificity improves diagnostic sensitivity and specificity. Neurology 1997, 48:989-997.
17. Grober E., Buschke H., Crystal H., et al. Screening for dementia by memory testing. Neurology 1988, 38:900-903.
18. Ivanoiu A., Adam S., Van der Linden M., et al. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease. JNeurol 2005, 252:47-55.
19. Sarazin M., Berr C., De Rotrou J., et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007, 69:1859-1867.
20. Sarazin M., Chauvire V., Gerardin E., et al. The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. JAlzheimers Dis 2010, 22:285-294.
21. Moscovitch M., Rosenbaum R.S., Gilboa A., et al. Functional neuroanatomy of remote episodic, semantic and spatial memory: a unified account based on multiple trace theory. JAnat 2005, 207:35-66.
22. Markesbery W.R., Schmitt F.A., Kryscio R.J., et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006, 63:38-46.
23. Pillon B., Blin J., Vidailhet M., et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995, 45:1477-1483.
24. Fossati P., Coyette F., Ergis A.M., et al. Influence of age and executive functioning on verbal memory of inpatients with depression. JAffect Disord 2002, 68:261-271.
25. Traykov L., Baudic S., Raoux N., et al. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. JNeurol Sci 2005, 229-230:75-79.
26. Lavenu I., Pasquier F., Lebert F., et al. Explicit memory in frontotemporal dementia: the role of medial temporal atrophy. Dement Geriatr Cogn Disord 1998, 9:99-102.
27. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
28. Blennow K., Hampel H., Weiner M., et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6(3):131-144.
29. Frisoni G.B., Fox N.C., Jack C.R., et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6:67-77.
30. Lehericy S., Marjanska M., Mesrob L., et al. Magnetic resonance imaging of Alzheimer's disease. Eur Radiol 2007, 17:347-362.
31. Yuan Y., Gu Z.X., Wei W.S. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. AJNR Am J Neuroradiol 2009, 30:404-410.
32. McDonald C.R., McEvoy L.K., Gharapetian L., et al. Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology 2009, 73:457-465.
33. Jack C.R., Dickson D.W., Parisi J.E., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
34. Korf E.S., Wahlund L.O., Visser P.J., et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004, 63:94-100.
35. Scheltens P., Pasquier F., Weerts J.G., et al. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal aging. Eur Neurol 1997, 37:95-99.
36. Chupin M., Gerardin E., Cuingnet R., et al. Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 2009, 19:579-587.
37. Colliot O., Chetelat G., Chupin M., et al. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology 2008, 248:194-201.
38. Dougall N.J., Bruggink S., Ebmeier K.P. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004, 12:554-570.
39. Habert M.O., Horn J.F., Sarazin M., et al. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiol Aging 2011, 32:15-23.
40. Patwardhan M.B., McCrory D.C., Matchar D.B., et al. Alzheimer disease: operating characteristics of PET-a meta-analysis. Radiology 2004, 231:73-80.
41. Tapiola T., Alafuzoff I., Herukka S.K., et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389.
42. Hansson O., Zetterberg H., Buchhave P., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
43. Buerger K., Ewers M., Pirttila T., et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006, 129:3035-3041.
44. de Souza L.C., Chupin M., Lamari F., et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging 2011, [Epub ahead of print]. 10.1016/j.neurobiolaging.2011.02.022.
45. de Souza L.C., Lamari F., Belliard S., et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. JNeurol Neurosurg Psychiatry 2010, 82:240-246.
46. Bian H., Van Swieten J.C., Leight S., et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008, 70:1827-1835.
47. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Post-mortem correlates of invivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
48. Fodero-Tavoletti M.T., Rowe C.C., McLean C.A., et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. JNucl Med 2009, 50:198-204.
49. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
50. Rabinovici G.D., Jagust W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis invivo. Behav Neurol 2009, 21:117-128.
51. Johnson K.A., Gregas M., Becker J.A., et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007, 62:229-234.
52. Koivunen J., Scheinin N., Virta J.R., et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011, 76:1085-1090.
53. Okello A., Koivunen J., Edison P., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760.
54. Rabinovici G.D., Jagust W.J., Furst A.J., et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008, 64:388-401.
55. de Souza L.C., Corlier F., Habert M.O., et al. Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011, 134:2036-2043.
56. Rosenbloom M.H., Alkalay A., Agarwal N., et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011, 76:1789-1796.
57. Edison P., Rowe C.C., Rinne J.O., et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. JNeurol Neurosurg Psychiatry 2008, 79:1331-1338.
58. Engler H., Santillo A.F., Wang S.X., et al. Invivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 2008, 35:100-106.
59. Alladi S., Xuereb J., Bak T., et al. Focal cortical presentations of Alzheimer's disease. Brain 2007, 130:2636-2645.